Philips
(NYSE: PHG)
announced today that it launched its Smart Quant Neuro 3D for brain disorder diagnosis and therapy.
The company unveiled the system at ECR2024 in partnership with Swedish MRI software solutions company SyntheticMR. Smart Quant Neuro 3D provides objective decision support for disorders like multiple sclerosis (MS), traumatic brain injury (TBI), and dementia.
According to a news release, the technology provides auto-measurement of various brain tissues. This enhances decision support of rain disease and helps assess progression and monitor the effect of therapy. Its analysis of myelin volumes also provides objective assessments for traumatic brain injuries. Previously, these were only diagnosed through symptom-based tests, Philips says.
The platform combines Philips’ AI-based SmartSmeed image-reconstruction technology and 3D syntAc with SyntheticMR’s SyMRI Neuro 3D quantitative tissue assessment software. This combination provides more tools for greater diagnostic confidence. Philips said this collaboration makes it the only company offering SyMRI Neuro 3D capabilities on MR scanners.
Philips and SyntheticMR’s combined offering leverages AI to provide fully verified, automatic, precise 3D segmentation and volume measurement of brain tissue. That includes white matter, gray matter, cerebrospinal fluid, and myelin.
“Life-changing brain injury and neurodegenerative disease are two of the most difficult diagnoses that clinicians have to make on a daily basis, because of the different symptoms exhibited by individual patients,” said Ruud Zwerink, business leader of MR at Philips. “With Smart Quant Neuro 3D, clinicians have access to an easy-to-use tool to provide valuable quantitative data to track the impact of treatments and make informed decisions about adjustments or alternative interventions as needed. This continuous monitoring enhances patient care by enabling proactive management of neurological conditions and optimizing therapeutic outcomes for patients.”